Rain Therapeutics Inc. (RAIN): Price and Financial Metrics
GET POWR RATINGS... FREE!
RAIN Stock Price Chart Interactive Chart >
RAIN Price/Volume Stats
| Current price | $2.50 | 52-week high | $22.22 |
| Prev. close | $2.32 | 52-week low | $2.15 |
| Day low | $2.30 | Volume | 62,500 |
| Day high | $2.56 | Avg. volume | 69,958 |
| 50-day MA | $4.15 | Dividend yield | N/A |
| 200-day MA | $10.59 | Market Cap | 66.28M |
Rain Therapeutics Inc. (RAIN) Company Bio
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Latest RAIN News From Around the Web
Below are the latest news stories about Rain Therapeutics Inc that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Highlights of Recent Progress on March 3, 2022NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and highlights of recent progress on Thursday, March 3, 2022. On that day, management will host a conference call and webcast at 1:30 pm PT (4:30 pm ET) to discuss the Company’s business and financial results. Conference Cal |
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapitalIn this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […] |
Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations – – In addition, Rain announces Advisory role to the CEO and Leadership team of John Maraganore, Ph.D., a position held since March 2021 – NEWARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) today announced the appointments of several industry veterans to the leadership team, including: Nora Ku, MD, Vice President of Clinical Deve |
Rain Therapeutics to Present at SVB Leerink Global Healthcare ConferenceNEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview followed by a moderated Q&A at the virtual SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18th at 1:40 pm ET. Additional details can be found below: Conference: SVB Leerink Glob |
Rain Therapeutics to Present at Upcoming Virtual Investor ConferencesB. Riley Securities virtual presentation scheduled for January 27th at 3:30 pm ET Guggenheim Oncology virtual fireside chat scheduled for February 10th at 4:00 pm ET NEWARK, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the B. Riley Securities Oncology I |
RAIN Price Returns
| 1-mo | -39.02% |
| 3-mo | -60.57% |
| 6-mo | -81.83% |
| 1-year | -87.42% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -80.59% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...